Overview
Nuclear Matrix Protein 22 is a protein associated with the nuclear matrix and plays a role in maintaining nuclear architecture, DNA transcription, and RNA synthesis. In cancerous urothelial cells, the concentration of Nuclear Matrix Protein 22 is significantly higher than in normal cells, with levels reported to be up to eighty times greater. During apoptosis or necrosis of bladder tumor cells, Nuclear Matrix Protein 22 is released into urine either as cleavage fragments or protein complexes. Because of this mechanism, NMP22 has emerged as a non-invasive urinary tumor marker for bladder cancer. The NMP22 BladderChek test is an antibody-based assay designed to detect this protein in urine and is commonly used as an adjunct tool in bladder cancer detection and surveillance.
Symptoms
Nuclear Matrix Protein 22 itself does not cause clinical symptoms. Testing is performed in patients with symptoms or clinical suspicion of bladder cancer. These may include hematuria, dysuria, increased urinary frequency, urgency, pelvic discomfort, or recurrent urinary tract symptoms. In many cases, testing is also done in asymptomatic individuals who are at high risk or in patients with a known history of bladder cancer undergoing follow-up.
Causes
Elevated urinary NMP22 levels occur due to increased release of nuclear matrix protein from apoptotic or necrotic urothelial tumor cells. Bladder cancer cells have a high nuclear turnover rate, leading to increased shedding of NMP22 into urine. While bladder cancer is the primary cause of persistently elevated levels, other conditions associated with increased cell death or inflammation in the urinary tract may also result in elevated NMP22, contributing to false positive results.
Risk Factors
Risk factors for elevated NMP22 levels and bladder cancer include smoking, occupational exposure to industrial chemicals, chronic bladder irritation, prior bladder cancer, and increasing age. Patients undergoing surveillance after bladder cancer treatment are a key group in whom NMP22 testing is commonly used. Interpretation may be affected by urinary tract infections, stones, recent instrumentation, or hematuria, all of which can increase nuclear protein release and reduce test specificity.
Prevention
There are no preventive measures to stop NMP22 release, as it reflects underlying cellular turnover and disease processes. Prevention in a clinical context focuses on the appropriate use and interpretation of the test. Correct sample collection using voided urine without preservatives or fixatives is essential. NMP22 should not be used as a standalone diagnostic tool and does not replace cystoscopy. A positive test warrants further evaluation, typically with cystoscopy, while a negative test does not exclude bladder cancer. When used appropriately alongside clinical assessment, cytology, and cystoscopy, NMP22 testing supports early detection, monitoring of recurrence, and surveillance of bladder cancer.
